you know, really excited today with what happened here in chicago with tempus getting public, pricede, trading up by the end of the day. that's good, anything that's working in their case, applying a.i. for diagnostic tools to make sure we're selecting the right patients to treat them with the right drugs and do that in a very rapid fashion. that's going to be really cost effective on the back end. >> john, great to speak with you, we hope you come back soon. >> it's a pleasure. >>> so many fascinating things going on out there. >> he was really good. and, you know, look, i think it speaks to a couple things. tim talks about this. competition is coming, without question. on the flipside of the coin is, in order to be competitive a lot of these companies are going to have to buy things and the structure therapeutics, i mean, i think my sue had a piece, a no-brainer takeout candidate and the stock is pulled back from 56 down to 48. that's really interesting here. >> what you're seeing in the space is glp-1s are the a.i. of the pharmaceutical space and they really need a lot of those pl